| Peer-Reviewed

Ameliorative Effect of Selenium Yeast on Blood Glucose Level in Streptozotocin Induced Diabetes in Wistar Rats

Received: 9 January 2015     Accepted: 15 January 2015     Published: 27 January 2015
Views:       Downloads:
Abstract

The study investigated the effect of selenium-yeast on Blood glucose level in streptozotocin induced diabetic wistar rats. Diabetes mellitus was induced by single intraperitoneal (i.p) injection of streptozotocin dissolved in 0.1ml fresh cold citrate buffer pH 4.5 at a dose of 60 mg/kg body weight, after which the rats were randomly divided into seven groups. Group 1 Diabetic treated with 0.1 mg/kg of selenium-yeast. Group 2 Diabetic treated with 0.2 mg/kg of selenium-yeast respectively. Group 3 Diabetic treated with 1 mg/kg of Glibenclamide (GB). Group 4 served as normoglycemic control group and was administered normal saline (5ml/kg), Group 5 Diabetic untreated group received normal saline (5ml/kg), Group 6 Diabetic treated with 300mg/kg moderate dose of Aspirin. Group 7 Diabetic treated with 120 mg/kg of Ibuprofen. All treatments were given orally for two weeks. The results of the present study showed that blood plasma glucose level in the diabetic control group was significantly higher when compared with the normal control group in the entire 4-weeks of the study. Blood plasma glucose levels were significantly lower (p < 0.05) in the Group treated with 0.2 mg/kg selenium-yeast and the standard drug Glibenclamide at WK1 and WK3 when compared with the diabetic control Group. In conclusion. The above results suggest that Selenium-yeast has shown to possess hypoglycaemic property that is comparable to the oral-hypoglycaemic drug, glibenclamide.

Published in Cell Biology (Volume 3, Issue 1)
DOI 10.11648/j.cb.20150301.12
Page(s) 14-18
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Selenium-Yeast, Streptozotocin, Glibenclamide, Aspirin, Ibuprofen

References
[1] World Health Organization (2010). Diabetes mellitus report of a WHO study Group,
[2] World Health Organization (WHO) (2008). Obesity. Available at: www.who/obesity.org
[3] Ime, F.A., Atangwho, I.J., Regina, I., Ejemot-Nwadiaro, I., Edisua, H.I. and Essien, U. (2011). Hypoglycaemic effect and proximate composition of some selected Nigerian traditional diets used in management of diabetes mellitus; European Journal of Food Research and Review, 1(2): 94- 101.
[4] Otieno, F.F. (2006). Clinical care of type 2 diabetes in sub-Saharan Africa. International Diabetes Monitoring, 18: 5–11.
[5] Peltzer, K., Khoza, L.B. and Lekhuleni, M.E. (2001). Concepts and treatment for diabetes among traditional and faith healers in the northern province, South Africa. Curationis Journal, 24: 42–7.
[6] Levitt, N.S. (2008). Diabetes in Africa: epidemiology, management and healthcare challenges. 695 Heart, 94 (11): 1376-1382.
[7] Thomson, C.D. (2004). Assessment of requirements for selenium and adequacy of selenium status: a review. European Journal of Clinical Nutrition., 58:391-402.
[8] Tinggi, U. (2008). Selenium: its role as antioxidant in human health. Environmental Health and Preventive Medicine, 13:102–108.
[9] Yiming, X., Kristina, E., Daniel, W., Jiayuan, X. and Raymond, F. (2005). Effectiveness of selenium supplements in a low-selenium area of China. American Journal of Clinical Nutrition, 81(4): 829-834.
[10] Schrauzer, G. (2000). Selenomethionine: A review of its nutritional significance, metabolism and toxicity. Journal of Nutrition, 130:1653-1656.
[11] Lovell, M, Xiong, S., Lyubartseva, G.andMarkesbery, W. (2009) (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. Free Radical Biology and Medicine, 46:1527-1533.
[12] Al-Othman, Z.A., Aboul-Soud, M., Al-Othman, A.M., El-Desoky, G.E., Yusuf K, A. J. and Al-Khedhairy, A.A (2011). Hepatoprotective Effects of Vitamin E/Selenium against Malathion-Induced Injuries on the antioxidant Status and Apoptosis-Related Gene Expression in Rats. Journal ofToxicological Science, 36: 285-296.
[13] Hammadi, S.H., Saeed, S.A., Ahmad, I.Y., Saad, D.A. (2012). Aspirin and Blood Glucose and Insulin Resistance. Open Journal of Endocrine and Metabolic Diseases, 2, 16-26.
[14] Beach, E.F., Turner, J.J. (1958). An enzymatic method for glucose determination in body fluid.Clinical chemistry, 4:462-468
[15] Rheney, C.C., Kirk, K.K. (2000). Performance of three blood glucose meters. Annal of Pharmacother. March, 34(3): 317-21.
[16] Laclaustra, M., Navas-Acien, A., Stranges, S., Ordovas, J.M. and Guallar, E. (2009). Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environmental Health Perspective, 117:1409-1413.
[17] Bleys, J., Navas-Acien, A. and Guallar E. (2007). Serum selenium and diabetes in U.S. adults. Diabetes. Care, 30:829-834.
[18] Czernichow, S., Couthouis, A., Bertrais, S., Vergnaud, A.C., Dauchet, L., Galan, P. and Hercberg S. (2006). Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. American Journal of Clinical Nutrition, 84:395-399.
[19] Stranges, S., Marshall, JR., Natarajan, R., Donahue, R.P., Trevisan, M., Combs, G.F., Cappuccio, F.P., Ceriello, A. and Reid, M.E. (2007). Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Annals of Intern ational Medicine, 147:217-223.
[20] Stapleton, S.R. (2000). Selenium: an insulin-mimetic. Cellular and Molecullar Life Sciences, 57:1874-1879.
[21] Mueller, A.S. and Pallauf, J. (2006). Compendium of the antidiabetic effects of supra-nutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. Journal of Nutrition and Biochemistry, 17: 548-560.
[22] Lawal, H.A., Atiku,M.K., Khelpai, D.G. and Wannag, N.N. (2008). Hypoglycaemic and hypolipidaemic effects of the aqueous leaf extract of Murrayakoenigiiin normal andalloxan – diabetic rats. Nigerian Journal of PhysiologicalSciences 23 (1-2): 37-40
[23] Rocourt, C.R. and Cheng, W.H. (2013). Selenium supranutrition: Are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutrients; 5(4):1349–65.
[24] Nouf, M. A., Hala, A. A., Raeesa, A. M., Nawal, M. A. and Maha, A. (2013). Preventive Effects of Selenium Yeast, Chromium Picolinate, Zinc Sulfate and their Combination on Oxidative Stress, Inflammation, Impaired Angiogenesis and Atherogenesis in Myocardial Infarction in Rats.Journal of Pharmacy and Pharmaceutical Sciences,16(5) 848 – 867
[25] Burcelin R., Eddouks M., Maury J., Kande J., AssanR.and Girard J. (1995). Excessive glucose production, rather than insulin resistance, accounts for hyperglycemia in recent-onset streptozotocin-diabetic diabetic rats. Diabetologia, 38, 283–290.
Cite This Article
  • APA Style

    Mohammed Kabir Ahmed, Mohammed Aliyu, Tanko Yusuf, Musa Kabir Yusuf. (2015). Ameliorative Effect of Selenium Yeast on Blood Glucose Level in Streptozotocin Induced Diabetes in Wistar Rats. Cell Biology, 3(1), 14-18. https://doi.org/10.11648/j.cb.20150301.12

    Copy | Download

    ACS Style

    Mohammed Kabir Ahmed; Mohammed Aliyu; Tanko Yusuf; Musa Kabir Yusuf. Ameliorative Effect of Selenium Yeast on Blood Glucose Level in Streptozotocin Induced Diabetes in Wistar Rats. Cell Biol. 2015, 3(1), 14-18. doi: 10.11648/j.cb.20150301.12

    Copy | Download

    AMA Style

    Mohammed Kabir Ahmed, Mohammed Aliyu, Tanko Yusuf, Musa Kabir Yusuf. Ameliorative Effect of Selenium Yeast on Blood Glucose Level in Streptozotocin Induced Diabetes in Wistar Rats. Cell Biol. 2015;3(1):14-18. doi: 10.11648/j.cb.20150301.12

    Copy | Download

  • @article{10.11648/j.cb.20150301.12,
      author = {Mohammed Kabir Ahmed and Mohammed Aliyu and Tanko Yusuf and Musa Kabir Yusuf},
      title = {Ameliorative Effect of Selenium Yeast on Blood Glucose Level in Streptozotocin Induced Diabetes in Wistar Rats},
      journal = {Cell Biology},
      volume = {3},
      number = {1},
      pages = {14-18},
      doi = {10.11648/j.cb.20150301.12},
      url = {https://doi.org/10.11648/j.cb.20150301.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cb.20150301.12},
      abstract = {The study investigated the effect of selenium-yeast on Blood glucose level in streptozotocin induced diabetic wistar rats. Diabetes mellitus was induced by single intraperitoneal (i.p) injection of streptozotocin dissolved in 0.1ml fresh cold citrate buffer pH 4.5 at a dose of 60 mg/kg body weight, after which the rats were randomly divided into seven groups. Group 1 Diabetic treated with 0.1 mg/kg of selenium-yeast. Group 2 Diabetic treated with 0.2 mg/kg of selenium-yeast respectively. Group 3 Diabetic treated with 1 mg/kg of Glibenclamide (GB). Group 4 served as normoglycemic control group and was administered normal saline (5ml/kg), Group 5 Diabetic untreated group received normal saline (5ml/kg), Group 6 Diabetic treated with 300mg/kg moderate dose of Aspirin. Group 7 Diabetic treated with 120 mg/kg of Ibuprofen. All treatments were given orally for two weeks. The results of the present study showed that blood plasma glucose level in the diabetic control group was significantly higher when compared with the normal control group in the entire 4-weeks of the study. Blood plasma glucose levels were significantly lower (p < 0.05) in the Group treated with 0.2 mg/kg selenium-yeast and the standard drug Glibenclamide at WK1 and WK3 when compared with the diabetic control Group. In conclusion. The above results suggest that Selenium-yeast has shown to possess hypoglycaemic property that is comparable to the oral-hypoglycaemic drug, glibenclamide.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Ameliorative Effect of Selenium Yeast on Blood Glucose Level in Streptozotocin Induced Diabetes in Wistar Rats
    AU  - Mohammed Kabir Ahmed
    AU  - Mohammed Aliyu
    AU  - Tanko Yusuf
    AU  - Musa Kabir Yusuf
    Y1  - 2015/01/27
    PY  - 2015
    N1  - https://doi.org/10.11648/j.cb.20150301.12
    DO  - 10.11648/j.cb.20150301.12
    T2  - Cell Biology
    JF  - Cell Biology
    JO  - Cell Biology
    SP  - 14
    EP  - 18
    PB  - Science Publishing Group
    SN  - 2330-0183
    UR  - https://doi.org/10.11648/j.cb.20150301.12
    AB  - The study investigated the effect of selenium-yeast on Blood glucose level in streptozotocin induced diabetic wistar rats. Diabetes mellitus was induced by single intraperitoneal (i.p) injection of streptozotocin dissolved in 0.1ml fresh cold citrate buffer pH 4.5 at a dose of 60 mg/kg body weight, after which the rats were randomly divided into seven groups. Group 1 Diabetic treated with 0.1 mg/kg of selenium-yeast. Group 2 Diabetic treated with 0.2 mg/kg of selenium-yeast respectively. Group 3 Diabetic treated with 1 mg/kg of Glibenclamide (GB). Group 4 served as normoglycemic control group and was administered normal saline (5ml/kg), Group 5 Diabetic untreated group received normal saline (5ml/kg), Group 6 Diabetic treated with 300mg/kg moderate dose of Aspirin. Group 7 Diabetic treated with 120 mg/kg of Ibuprofen. All treatments were given orally for two weeks. The results of the present study showed that blood plasma glucose level in the diabetic control group was significantly higher when compared with the normal control group in the entire 4-weeks of the study. Blood plasma glucose levels were significantly lower (p < 0.05) in the Group treated with 0.2 mg/kg selenium-yeast and the standard drug Glibenclamide at WK1 and WK3 when compared with the diabetic control Group. In conclusion. The above results suggest that Selenium-yeast has shown to possess hypoglycaemic property that is comparable to the oral-hypoglycaemic drug, glibenclamide.
    VL  - 3
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Human Physiology, Ahmadu Bello University, Zaria, Kaduna State, Nigeria

  • Department of Human Physiology, Ahmadu Bello University, Zaria, Kaduna State, Nigeria

  • Department of Human Physiology, Ahmadu Bello University, Zaria, Kaduna State, Nigeria

  • Department of Phamacognosy and Drug Design, Ahmadu Bello University, Zaria, Kaduna State, Nigeria

  • Sections